A New Drug Application was submitted to the FDA for a novel, nonhormonal dual neurokinin-1 and neurokinin-3 receptor antagonist for the treatment of menopause-related vasomotor symptoms.
About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the menopause phase. For most, the symptoms are manageable, but for a sizeable subset of midlife [...]
Over the last few years, we have seen a number of articles suggesting that the burden of menopausal symptoms is probably greater than generally perceived.  About 80% of women experience vasomotor symptoms (VMS) – hot [...]
